Development of a K562 cell-based assay for screening anticancer agents

Acta Pharmacol Sin. 2001 Sep;22(9):821-6.

Abstract

Aim: To develop a leukemia cell line K562-based assay for high-throughput screening.

Methods: The screening was carried out on 96-well plates with monitoring cell proliferation by a combined 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium (MTS)/phenazine methosulfate (PMS) method. Conditions for evaluating effects on the proliferation of K562 cells by individual compounds on the 96-well plates were optimized.

Results: A set of 800 small organic compounds was screened for anticancer activity by this cell-based assay, with consumption of each compound at 500 ng. Eleven compounds were identified with >80 % inhibitory activity at 5 mg/L, among which 9 compounds were confirmed by subsequent testing at multiple concentrations. The most potent compound showed an IC50 at 170 nmol/L, and there were total of 7 compounds showed IC50 less than 10 micromol/L.

Conclusion: The high-throughput method using K562 cell line is fast, economical, effective, and practical in identifying inhibitors as potential therapeutic agents for cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Division
  • Drug Screening Assays, Antitumor / methods*
  • Humans
  • K562 Cells* / cytology
  • K562 Cells* / drug effects
  • Tetrazolium Salts

Substances

  • Tetrazolium Salts